

Manuscripts

Preoperative Back Pain Severity Influences Postoperative Clinical Outcomes and Trajectory in Patients Undergoing Lateral Lumbar Interbody Fusion

Kevin Jacob^{1a}, Madhav Patel^{1b}, Shashank Patil^c, James Nie^{2d}, Timothy Hartman^{2e}, Nisheka Vanjani^{2f}, Michael Prabhu^{2g}, Hanna Pawlowski^{2h}, Kern Singh²ⁱ

¹ Rush University Medical Center, ² Orthopedics, Rush University Medical Center

Keywords: Preoperative Back Pain Severity, Patient-reported outcome measures

<https://doi.org/10.60118/001c.37424>

Journal of Orthopaedic Experience & Innovation

Vol. The Singh Series: Research in Spine Surgery, Issue 1, 2022

Background

The Visual Analog Scale (VAS) is a frequently used and validated instrument for assessing a patient's self-perceived lower back and leg pain and is often employed to assess the efficacy of lumbar surgical intervention. Our study seeks to assess how preoperative severity of presenting lumbar back pain may influence postoperative clinical trajectory and patient-reported outcome measures (PROMs) following lateral lumbar interbody fusion (LLIF)

Objective

To compare perioperative and postoperative mean patient-reported outcome measures and minimum clinical important difference (MCID) achievement following LLIF in patients stratified by preoperative back pain.

Methods

A prospectively maintained surgical database was retrospectively reviewed for lumbar operations between June 2005 and December 2021. Inclusion criteria was set as primary, elective, single or multi-level LLIF procedures for degenerative lumbar spinal pathology. Patients undergoing a revision procedure, or surgery indicated for infectious, malignant, or traumatic etiologies were excluded. Additionally, patients who did not fill out a preoperative VAS back survey were excluded as well. Patient demographics, perioperative characteristics, and PROMs were collected. PROMs were administered at preoperative and 6-week, 12-week, 6-month, 1-year, and 2-year postoperative time-points and included Patient-Reported Outcomes Measurement Information System- Physical Function (PROMIS-PF), Visual Analogue Scale (VAS) for back and leg pain, Oswestry Disability Index (ODI), and 12-Item Short Form Physical Composite Score (SF-12 PCS).

a [Conflicts of Interest Statement for Dr. Jacob](#)

b [Conflicts of Interest Statement for Dr. Patel](#)

c [Conflicts of Interest Statement for Dr. Patil](#)

d [Conflicts of Interest Statement for Dr. Nie](#)

e [Conflicts of Interest Statement for Dr. Hartman](#)

f [Conflicts of Interest Statement for Dr. Vanjani](#)

g [Conflicts of Interest Statement for Dr. Prabhu](#)

h [Conflicts of Interest Statement for Dr. Pawlowski](#)

i [Conflicts of Interest Statement for Dr. Singh](#)

[Visit the Open Payments Data Page for Dr. Singh](#)

Postoperative complications were collected for each group as well. Patients were grouped into two cohorts, depending on whether a patient had a preoperative VAS back score of < (mild to moderate back pain cohort or VAS back score ≥ 7 (Severe back pain cohort). Demographic and perioperative characteristics were compared among groups using chi-square and Student's t-test for categorical and continuous variables, respectively. Mean PROM scores were compared between cohorts at each time point utilizing a unpaired Student's t-test. Postoperative improvement from preoperative baseline within each cohort was assessed with paired samples t-test. Achievement of Minimum Clinical Important Difference (MCID) was determined by comparing Δ PROM scores to previously established threshold values. MCID achievement rates were compared between groups with chi-squared analysis.

Results

Patient cohort consisted of 199 patients – 84 patients in VAS back preoperative <7 and 115 patients in the VAS back Preoperative ≥ 7 cohort (Table 1). Significant demographic differences between cohorts were noted for hypertensive status with VAS back Preoperative < 7 cohort having significantly higher rates of hypertension ($p < 0.029$) (Table 1). The majority of patient cohort were male (51.8%), Caucasian (80.8%), non-smokers (81.6%), non-diabetic (85.9%) and utilizing private insurance (62.8%). Majority of patients in both cohorts had presenting spinal pathology of Degenerative Spondylolisthesis (50.8%) with concomitant central stenosis (86.9%) (Table 2). A significantly greater proportion of patients in VAS back preoperative < 7 cohort reported central and foraminal stenosis. No significant differences were noted between cohorts for operative duration, estimated blood loss, or postoperative day of discharge. Patients in the severe back pain cohort demonstrated significantly greater mean postoperative length of stay (53.9 hrs vs 40.6 hrs), greater postoperative VAS pain scores on POD0 and 1, and greater postoperative narcotic consumption on POD1 ($p < 0.049$, all) (Table 2).

Rate of postoperative complications did not differ between cohorts. Preoperative mean PROM scores were significantly different for all PROMs collected (Table 4). Cohorts demonstrated significant mean postoperative differences for the following PROMs at the following postoperative time points: VAS back at 6-weeks, 12-weeks, 6-months, and 2-years, VAS leg at 6-months, ODI at 6-weeks, 12-weeks, 6-months, and 2-years, SF-12 PCS at 6-months, and PROMIS-PF at 12-weeks, 6-months, and 1-year ($p < 0.049$, all) (Table 4). Preop VAS back <7 patient cohort demonstrated improvement from preoperative baseline to the 2-year time point for all PROMs collected at all individual postoperative timepoints with the exception of VAS leg at 1-year, ODI at 6-weeks, SF-12 PCS at 6-weeks, and PROMIS-PF at 6-weeks. (Table 4). Preop VAS back ≥ 7 patient cohort demonstrated improvement from preoperative baseline to 2-year time point for all PROMs collected at all individual postoperative timepoints (Table 4). Patients in the VAS back ≥ 7 patient cohort demonstrated greater proportion achieving MCID for VAS back at 6-weeks, 12-weeks, 1-year, and overall as well as for VAS leg at 6-weeks ($p < 0.043$, all) (Table 5).

Conclusion

Patients in both preoperative back pain severity cohorts demonstrated significant long term clinical improvement from their respective preoperative baselines at 2-years postoperatively for back pain, leg pain, physical function, and general disability. Patients with severe preoperative back pain (VAS >7), however, demonstrated significantly inferior short (6weeks-6months) and long term (2-year) mean outcome scores for back pain and general disability. 2-year mean outcome scores for leg pain and physical function were similar between cohorts. Results from our study may be used by surgeons to understand differing postoperative trajectories of patients undergoing LLIF stratified by back pain severity.

INTRODUCTION

Low back pain (LBP) is a major contributor of disability and disease burden worldwide, requiring significant resources in the diagnosis and treatment of patients (Hoy et al. 2014).

LBP may be present in all age groups, but prevalence is higher in aging populations and those with comorbid diseases (Wong, Karppinen, and Samartzis 2017). Pathologies affecting the lower back have variable symptomatic presentations, including radiculopathy, myelopathy, point tender-

ness, and disability. While conservative treatment should be started early in patients with mild to moderate symptoms, more severe or treatment resistant pathologies may require surgery to alleviate the underlying anatomical deformity responsible for symptoms (Mobbs et al. 2015). Of the various surgical options, the lateral lumbar interbody fusion (LLIF) technique may be indicated for all degenerative pathologies of the lumbar spine (Mobbs et al. 2015). First described by Ozgur et al. in 2006, the disc space is accessed via a lateral retroperitoneal transpsoas corridor. The LLIF involves a minimally invasive (MIS) muscle-splitting approach, allowing for rapid postoperative mobilization. Furthermore, the MIS approach has demonstrated reduced operative time, decreased blood loss, and shorter hospital stays than comparable open procedures (Patel, Zfass-Mendez, Lewohl, et al. 2015). Due to the lateral approach, the method is particularly effective at sagittal and coronal deformity correction in lumbar degenerative scoliosis with laterolisthesis (Arnold, Anderson, and McGuire 2012). The LLIF technique is suitable to access the T12/L1 to L4/L5 disc spaces, however more caudal segments may be obstructed by the iliac crest and are at higher risk for lumbar plexus, iliac vessel, and bowel injury.

Measures of success in spine surgery have recently shifted to evaluate patient reported outcome measures (PROMs), as they demonstrate the patient's perspective of their health-related status. While subjective in nature, these patient-centered metrics often act as an adjunct to clinical and radiographic findings, allowing for the development of a holistic assessment of surgical outcomes in the treatment of spinal pathologies (Finkelstein and Schwartz 2019). While past ideas of operative success consisted of objective clinical measures, current satisfaction assessment includes preoperative factors, the patient's interpersonal relationships with the treatment team, and PROMs (Menendez et al. 2019). Outcome assessment using PROMs has demonstrated quality of care and cost effectiveness, and has established the patient perspective as playing a leading role in the treatment plan (Finkelstein and Schwartz 2019). Furthermore, utilizing PROM scores, the minimum clinically important difference (MCID) achievement may be determined to quantify improvements that may yield significant benefit to functional, pain, or mental status metrics. Commonly used PROMs in the assessment of lumbar surgical outcomes include the Visual Analog Scale (VAS) for pain in the back and leg, Oswestry Disability Index (ODI), 12-Item Short-Form for Physical Composite Score, (SF-12 PCS), and Patient-Reported Outcomes Measurement Information System for Physical Function

(PROMIS-PF) (McCormick, Werner, and Shimer 2013; Bernstein et al. 2019).

While prior literature has established that preexisting comorbid conditions may have a negative effect on lumbar spine surgery outcomes, the effect of preoperative PROM values on postoperative success and patient satisfaction has not been thoroughly investigated. By stratifying patients undergoing LLIF by preoperative back pain severity to determine differences in PROM scores and MCID, surgeons can be informed of determinants that may alter expected postoperative outcomes. These findings may be used in the development of realistic postoperative expectations for individuals at risk for poor surgical improvement, thus allowing patients to make appropriately informed decisions regarding their treatment. Therefore, the aim of the current study is to provide an evaluation of the predictive capacity of preoperative back pain severity on postoperative PROM and MCID achievement following LLIF. Utilizing the findings from this study, we hope surgeons will garner a better understanding of factors predicting postoperative success, thereby leading to more favorable future outcomes following LLIF for lumbar pathologies.

METHODS

PATIENT POPULATION

Institutional Review Board (ORA #14051301) approval and informed patient consent were obtained prior to onset of the study. Surgical procedures were performed between June 2005 and December 2021 at a single academic institution by one surgeon. These operations were retrospectively identified in a prospectively maintained database cataloging surgical outcomes. Patients were included in this study if they received primary, elective, single or multi-level LLIF procedures for degenerative lumbar spinal pathologies. Patients were excluded if they received surgery for traumatic, malignant, or infectious etiologies. Additionally, patients who did not fill out a preoperative VAS back survey were excluded as well.

DATA COLLECTION

Patients were separated into two cohorts by their preoperative VAS back pain score. The first cohort (moderate back pain) reported preoperative VAS back scores ≤ 7 , while the second (severe back pain) reported scores >7 . VAS back scores of 7 were chosen as the cutoff point to indicate severe back pain, as Boonstra et al. defined VAS >6.5 as severe with regard to impact on functioning, and VAS >7.5 as severe on the verbal rating scale. To account for the impact



©2022 Pacira Pharmaceuticals, Inc. a wholly owned subsidiary of Pacira Biosciences, Inc. All rights reserved. PP-NP-US-1328 05/22

***Advertisement**

[Click here to learn more about Pacira](#)

stryker

Is there anything better than a balanced knee?

Because isn't a **balanced knee** what it's all about?

Learn more about

VeraSense® for Triathlon® Sensor Technology

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery. The information presented is intended to demonstrate the breadth of Stryker's product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker's products.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area. Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Stryker, Triathlon, VeraSense.

VERAS-AD-9_33611 Copyright© Stryker 2022

*Advertisement

[Click here to learn more about VeraSense](#)

of pain on both verbal and functional scales, this study utilized a point of division at VAS back scores of 7.0.

Patient demographic information was collected, including age, body mass index (BMI), smoking status, the presence of diabetic and hypertensive comorbidities, American Society of Anesthesiologists (ASA) score to determine operative risk, Charlson Comorbidity Index (CCI) to assess for comorbid disease burden and insurance type. Perioperative characteristics were collected as well, detailing spinal pathology, number of operative levels, operative duration, estimated intraoperative blood loss (EBL), length of stay (LOS), and postoperative day of discharge. Other data regarding immediate postoperative pain scores, narcotic consumption, and 1-year arthrodesis rates were collected. Postoperative complications were analyzed among both cohorts.

PROMs were collected at baseline (preoperatively) and postoperatively at 6-weeks, 12-weeks, 6-months, 1-year, and 2-years for all metrics. The assessed PROMs included VAS back, VAS leg, ODI, 12-Item Short-Form for Physical Composite Score, SF-12 PCS, and PROMIS-PF. Minimum clinically important differences (MCID) were also determined for each PROM among cohorts at all postoperative timepoints.

STATISTICAL ANALYSIS

Stata 16.0 (StataCorp LP, College Station, TX) was used for data analysis. Descriptive characteristics including mean and standard deviation values were calculated for all demographic factors, perioperative characteristics, and PROM scores at each timepoint. Categorical data differences in demographic and perioperative data between cohorts were analyzed using Chi-square tests to determine significance, or with Student's t-tests for continuous variables. Mean PROM scores were compared between cohorts at each time interval with an unpaired Student's t-test. Postoperative improvement from baseline PROM scores within each cohort were assessed using a paired samples t-test. Achievement of MCID was determined by comparing the change in PROM values from baseline to previously established threshold values. MCID achievement rates were compared between groups with chi-squared analysis.

RESULTS

DESCRIPTIVE ANALYSIS

A total of 199 patients were included in this study, with 84 in the moderate VAS back cohort and 115 in the severe cohort. Demographically, both cohorts demonstrated similarities in average age (59.6 years), gender (48.2% female and 51.8% male), average BMI (30.3 kg/m²), and ethnicity. Patients in each cohort had a similar prevalence of diabetes (85.9% non-diabetic) and smoking status (81.6% non-smokers). Furthermore, no significant differences were observed regarding ASA classification, CCI, and insurance type between groups. Hypertensive status among cohorts varied significantly with 37.4% reporting hypertension in the moderate back pain cohort, compared to 53.0% in the severe back pain cohort ($p=0.029$) (Table 1). A significantly greater proportion of patients in the moderate back pain cohort experienced pathologies of central stenosis and foraminal stenosis than the severe back pain cohort ($p=0.034$ and $p=0.041$, respectively), but rates of herniated nucleus pulposus, degenerative spondylolisthesis, degenerative scoliosis, and isthmic spondylolisthesis were similar. As both single- and multi-level LLIF were included, both cohorts demonstrated a similar number of operative levels, which was most often a single level (73.1%). Intraoperative parameters, including operative duration (163.3 minutes) and estimated blood loss (96.8 mL), were similar among cohorts as well. Patients in both cohorts also experienced a similar postoperative day of discharge, which was most commonly day 1 in both groups (36.6%). However, the total LOS varied significantly among cohorts (40.6 hours in the moderate back pain cohort versus 53.9 hours in the severe back pain cohort, $p=0.011$). Furthermore, postoperative VAS pain scores on days 0 and 1 were significantly greater in the severe back pain cohort ($p=.008$ and $p=.013$, respectively), and day 1 narcotic consumption was significantly higher in the severe back pain cohort ($p=0.049$). One-year arthrodesis rates were 99.1% among both cohorts (Table 2). Postoperative complications among each cohort were similar, and were most commonly fever of unknown origin (10.6%), nausea/vomiting (7.5%), and urinary reten-

Table 1. Patient Demographics

	Total (n=199)	VAS- Back <7 (n=84)	VAS- Back ≥7 (n=115)	*p-value
Age (mean±SD)	59.6 ± 11.6	60.5 ± 11.2	58.9 ± 11.9	0.323
Gender				
Female	48.2% (96)	42.9% (36)	52.2% (60)	0.194
Male	51.8% (103)	57.1% (48)	47.8% (55)	
Body Mass Index (Mean ± SD)	30.3 ± 6.1	29.4 ± 5.7	30.9 ± 6.2	0.069
Ethnicity				
Caucasian	80.8% (160)	83.1% (69)	79.1% (91)	
African-American	6.6% (13)	6.0% (5)	6.9% (8)	
Hispanic	7.1% (14)	4.8% (4)	8.7% (10)	
Asian	2.0% (4)	2.4% (2)	1.7% (2)	0.862
Other	3.5% (7)	3.6% (3)	3.5% (4)	
Smoking Status				
Non-Smoker	81.6% (111)	79.1% (34)	82.8% (77)	0.602
Smoker	18.4% (25)	20.9% (9)	18.2% (16)	
Diabetes				
Non-Diabetic	85.9% (171)	86.9% (73)	85.2% (98)	0.735
Diabetic	14.1% (28)	13.1% (11)	14.8% (17)	
Smoking Status				
Non-Smoker	85.3% (168)	82.9% (68)	86.9% (100)	0.431
Smoker	14.7% (29)	17.1% (14)	13.0% (15)	
Hypertensive Status				
Non-Hypertensive	53.5% (106)	62.7% (52)	46.9% (54)	0.029
Hypertensive	46.5% (92)	37.4% (31)	53.0% (61)	
ASA Classification				
<3	70.1% (138)	68.7% (57)	71.1% (81)	0.719
≥ 3	29.9% (59)	31.3% (26)	28.9% (33)	
CCI Score (Mean ± SD)	3.1 ± 2.2	3.3 ± 2.4	2.9 ± 2.1	0.224
Insurance				
Medicare/Medicaid	21.1% (42)	15.5% (13)	25.2% (29)	
Workers' Compensation	16.1% (32)	11.9% (10)	19.1% (22)	0.050
Private	62.8% (125)	72.6% (61)	55.7% (64)	

ASA = American Society of Anesthesiologists

CCI = Charlson Comorbidity Index

tion (6.0%). No major postoperative complications were reported in either cohort ([Table 3](#)).

PRIMARY OUTCOME MEASURES

PROMs at nearly all postoperative time points were improved among each metric compared to baseline. The moderate back pain cohort experienced significant improvements at all timepoints for VAS back pain, significant benefits in VAS leg pain at all but 1-year follow-up, and ODI, SF-12 PCS, and PROMIS-PF at all but 6-weeks postoperatively ($p < 0.038$, all). The severe back pain cohort noted significant benefits from preoperative baseline PROM scores in all metrics at every time point ($p < 0.039$, all). Comparing PROM values among cohorts, the results were more

variable. Significant improvement was noted in the moderate back pain cohort over the severe back pain group for VAS back, ODI (all points except 1-year), and PROMIS-PF (12-weeks, 6-months, and 1-year) at most postoperative follow-ups. VAS leg and SF-12 PCS only noted significant benefit in the moderate pain cohort at 6-months ($p < 0.041$, both). Furthermore, all baseline preoperative PROM values significantly favored the moderate back pain cohort for each measure ($p < 0.003$, all) ([Table 4](#)). MCID achievement rates were similar between cohorts for PROMIS-PF, SF-12 PCS, and ODI at all intervals. VAS leg demonstrated significant differences in MCID achievement at 6-weeks postoperatively, and VAS back had differences at 6 weeks, 12 weeks, 1 year, and overall ($p < 0.043$, all). In the severe back pain

Table 2. Perioperative Characteristics

	Total (n=199)	VAS- Back <7 (n=84)	VAS- Back ≥7 (n=115)	*p-value
Spinal Pathology				
Central Stenosis	86.9% (173)	92.9% (78)	82.6% (95)	0.034
Foraminal Stenosis	38.2% (76)	46.4% (39)	32.2% (37)	0.041
Herniated Nucleus Pulposus	7.5% (15)	4.8% (4)	9.6% (11)	0.205
Degenerative Spondylolisthesis	50.8% (101)	47.6% (40)	53.0% (61)	0.450
Degenerative Scoliosis	32.2% (64)	36.9% (31)	28.7% (33)	0.221
Isthmic Spondylolisthesis	10.1% (20)	15.5% (13)	6.1% (7)	0.080
Number of Operative Levels				
Single Level	73.1% (144)	77.4% (65)	69.9% (79)	
Multiple Levels	26.9% (53)	22.6% (19)	30.1% (34)	0.242
Operative Time (Mean±SD; min)				
	163.3 ± 90.5	156.8 ± 87.0	167.9 ± 93.0	0.395
Estimated Blood Loss (Mean±SD; mL)				
	96.8 ± 176.4	103.1 ± 250.8	92.0 ± 84.8	0.673
1-year arthrodesis				
	99.1% (112)	97.2% (36)	100.0% (75)	-
Length of Stay (Mean±SD; hours)				
	48.3 ± 35.1	40.6 ± 31.8	53.9 ± 36.3	0.011
Postoperative Day of Discharge (POD)				
POD0	11.3% (21)	14.1% (11)	9.3% (10)	0.129
POD1	36.6% (68)	42.3% (33)	32.4% (35)	
POD2	23.1% (43)	26.9% (21)	20.4% (22)	
POD3	14.5% (27)	7.7% (6)	19.4% (21)	
POD4	8.6% (16)	6.4% (5)	10.2% (11)	
Postoperative VAS Pain Score				
POD0	5.4 ± 1.9	4.8 ± 1.9	5.7 ± 1.9	0.008
POD1	4.8 ± 1.8	4.2 ± 1.3	5.1 ± 1.9	0.013
Postoperative Narcotic Consumption (OME)				
POD0	61.2 ± 41.1	54.5 ± 32.5	66.0 ± 45.9	0.051
POD1	47.5 ± 47.6	39.7 ± 32.2	53.2 ± 55.7	0.049

OME = Oral Morphine Equivalents

POD = Postoperative Day

Re-hospitalization = Defined as returning to hospital within 6-weeks of surgery with a surgical related complaint.

cohort, MCID was most likely to be reached in VAS back and SF-12 PCS (83.3%), followed by VAS leg (77.2%) and PROMIS-PF (74.3%). The moderate back pain cohort was most likely to achieve MCID in SF-12 PCS (72.0%), followed by PROMIS-PF (67.4), however stark differences were noted among cohorts in MCID achievement for VAS back ([Table 5](#)).

DISCUSSION

INTRODUCTION

This study evaluated the predictive capacity of stratifying a patient cohort undergoing LLIF into moderate or severe preoperative back pain using the VAS to determine postoperative pain, disability, and functional status as measured through patient-reported outcome measures and achievement of MCID. Overall, the PROM data demonstrated significant postoperative improvements in VAS Back and Leg Pain, ODI, SF-12 PCS, and PROMIS-PF scores in both cohorts compared to their respective baselines. When the two co-

horts were compared, the moderate preoperative back pain cohort demonstrated significantly better short- and long-term VAS Back and ODI measures compared to the severe preoperative back pain cohort. This study also showed that patients with severe preoperative baseline back pain (VAS back score ≥7) had significantly longer LOS, greater VAS pain and narcotic consumption on day 0 and day 1 postoperatively, and higher MCID achievement for overall VAS back pain compared to patients with moderate preoperative back pain (VAS back score <7).

PERIOPERATIVE OUTCOMES

It is interesting to note that though back pain severity differed between groups, the surgical characteristics such as the number of operative levels, operative time, and EBL were similar. The average operative time (163min) and EBL (96.8ml) noted in both groups of this study were shorter and smaller respectively compared to a retrospective case series of 84 LLIF patients by Youssef et al (2010) which reported an average OR time of 199min and EBL of 155ml.

Table 3. Postoperative Complications

Complication	Total (n=199)	VAS-Back <7 (n=84)	VAS- Back ≥7 (n=115)	*p-value
Reintubation	0.0% (0)	0.0% (0)	0.0% (0)	-
Urinary Retention	6.0% (12)	9.5% (8)	3.5% (4)	0.077
Urinary Tract Infection	0.0% (0)	0.0% (0)	0.0% (0)	-
Acute Renal Failure	0.0% (0)	0.0% (0)	0.0% (0)	-
Altered Mental Status	2.0% (4)	0.0% (0)	3.5% (4)	0.084
VTE	0.0% (0)	0.0% (0)	0.0% (0)	-
Pulmonary Embolism	0.5% (1)	0.6% (1)	0.0% (0)	0.672
Pneumothorax	0.5% (1)	0.0% (0)	0.9% (1)	0.392
Pneumonia	0.5% (1)	0.0% (0)	0.9% (1)	0.392
Atelectasis	1.5% (3)	0.0% (0)	2.6% (3)	0.136
Pleural Effusion	0.5% (1)	0.0% (0)	0.9% (1)	0.392
Arrhythmia	0.5% (1)	1.2% (1)	0.0% (0)	0.241
Ileus	2.5% (5)	0.0% (0)	4.4% (5)	0.053
Nausea / Vomiting	7.5% (15)	4.8% (4)	9.6% (11)	0.205
Fever of Unknown Origin	10.6% (21)	7.1% (6)	13.0% (15)	0.392

VTE = venous thromboembolism

**BE A PART OF BETTER ORTHOPAEDIC CARE.
CLICK HERE TO LEARN HOW.**

THE ORTHOPAEDIC IMPLANT COMPANY



*Advertisement

[Click here to learn more about The Orthopaedic Implant Company](#)

Another study by Ahmadian et al (2013) examining 84 patients with LLIF for L4-5 spondylolisthesis found a mean EBL of 94ml - similar to the present study. The similar intra-operative parameters likely contributed to the similar rates of all postoperative complications between the groups. These findings suggest that subjective measures of pain severity may not necessarily correlate with the severity of spinal pathology anatomically in patients undergoing LLIF, though a future study examining this relationship would be necessary to provide clarity. Separately, though this study found significantly longer average LOS for patients with severe preoperative back pain based on number of hours (53.9hrs vs. 40.6hrs, $p=0.011$), this finding did not necessarily translate into a significant shift in postoperative day of discharge ($p=0.129$). One possible explanation for the discrepancy in length of stay between groups is the increased time required to monitor and treat the significantly higher postoperative pain observed on postoperative day (POD) 0 and 1 in the VAS ≥ 7 back pain cohort, though increased pain alone may not have significantly influenced the planned day of discharge.

CLINICAL OUTCOMES

As described previously, patients in both preoperative back pain cohorts saw statistically significant short- and long-term improvements in measures of pain, disability, and physical function post-operatively – findings consistent with existing literature of patients undergoing LLIF (Youssef et al. 2010; Ahmadian et al. 2013; Rodgers, Gerber, and Patterson 2011; Phillips et al. 2013; Salzmann, Shue, and Hughes 2017; Kotwal et al. 2015). In the retrospective study of 84 patients undergoing LLIF by Youssef et al, VAS improved by 77% and ODI improved by 56% from baseline at 1-year follow-up (2010). Similarly, in a prospective analysis of 600 patients undergoing XLIF, Rodgers et al found an immediate 65% improvement (8.82 to 3.12) in VAS pain score (2011). Further, Ahmadian et al (2013) analyzed 31 patients with L4-5-level stenosis and spondylolisthesis treated with LLIF without laminectomy and reported a 38.6% improvement in ODI and 44.6% improvement in VAS Back from pre-operation to last follow-up. In our study, we found a 25.5% and 36.2% improvement in VAS Back score in the moderate preoperative back pain group and 57% and 30.1% improvement in the severe back pain group at 1-year and 2-year follow-ups, respectively. Regarding ODI,

Table 4. Patient Reported Outcome Measures

	VAS-Back <7 Mean±SD	VAS-Back <7 Postoperative PROM Improvement	VAS-Back ≥7 Mean±SD	VAS-Back ≥7 Postoperative PROM Improvement	*p-value
VAS Back					
Preoperative	4.7 ± 1.7	-	8.3 ± 0.9	-	<0.001
6-weeks	3.3 ± 1.9	<0.001	4.2 ± 2.5	<0.001	0.012
12-weeks	2.6 ± 2.2	<0.001	3.6 ± 2.7	<0.001	0.017
6-months	2.0 ± 2.3	<0.001	3.5 ± 2.7	<0.001	0.003
1-year	3.5 ± 3.0	0.038	3.6 ± 2.9	<0.001	0.841
2-year	3.0 ± 2.6	<0.001	5.8 ± 3.4	0.006	0.049
VAS Leg					
Preoperative	4.8 ± 2.5	-	6.9 ± 2.2	-	<0.001
6-weeks	2.9 ± 2.7	<0.001	3.8 ± 2.5	<0.001	0.117
12-weeks	1.9 ± 2.2	<0.001	3.1 ± 2.8	<0.001	0.064
6-months	1.9 ± 2.6	<0.001	3.5 ± 2.7	0.002	0.026
1-year	3.1 ± 3.5	0.060	3.6 ± 2.9	<0.001	0.593
2-year	2.7 ± 2.7	0.018	4.9 ± 3.5	0.002	0.122
ODI					
Preoperative	32.9 ± 13.0	-	49.0 ± 15.0	-	<0.001
6-weeks	32.6 ± 16.7	0.981	39.1 ± 16.4	<0.001	0.045
12-weeks	21.1 ± 16.6	<0.001	35.4 ± 20.9	<0.001	0.001
6-months	19.1 ± 14.9	<0.001	29.6 ± 18.7	<0.001	0.010
1-year	24.8 ± 21.3	0.019	36.4 ± 25.6	0.013	0.091
2-year	19.6 ± 18.8	0.028	39.0 ± 22.5	0.017	0.043
SF-12 PCS					
Preoperative	31.9 ± 8.4	-	27.3 ± 6.8	-	0.003
6-weeks	32.6 ± 8.8	0.738	31.7 ± 9.5	0.012	0.651
12-weeks	37.8 ± 10.4	0.007	37.2 ± 11.1	<0.001	0.808
6-months	41.3 ± 11.4	0.004	35.1 ± 12.0	<0.001	0.041
1-year	41.7 ± 11.6	0.003	36.2 ± 13.4	0.003	0.122
2-year	43.6 ± 10.3	0.026	41.9 ± 12.4	0.004	0.691
PROMIS PF					
Preoperative	37.7 ± 5.5	-	31.7 ± 5.8	-	<0.001
6-weeks	37.9 ± 5.9	0.959	35.3 ± 6.1	0.039	0.075
12-weeks	42.0 ± 6.7	0.015	38.5 ± 6.9	<0.001	0.043
6-months	46.3 ± 8.4	<0.001	39.9 ± 7.2	<0.001	0.005
1-year	46.3 ± 6.9	<0.001	40.2 ± 9.2	0.001	0.014
2-year	44.2 ± 5.8	0.014	41.8 ± 7.4	0.026	0.414

*p-values calculated using paired samples t-test to determine postoperative improvement

our study found a 24.6% and 40.4% improvement in the moderate back pain group and 26.7% and 20.4% improvement in the severe back pain group at 1-year and 2-year follow-ups, respectively. Campbell et al's (2018) retrospec-

tive evaluation of 18 consecutive patients with Grade 1 or 2 spondylolisthesis found an average ODI and SF-12 PCS score improvement of 26 and 5.4 points respectively at the 6-month follow up. In our study, the moderate back pain

Table 5. MCID Achievement

PROM	VAS-Back <7	VAS-Back >=7	*p-value
VAS Back			
6-weeks	34.9%	72.7%	<0.001
12-weeks	44.5%	72.3%	0.002
6-months	56.5%	72.9%	0.068
1-year	33.3%	75.0%	0.005
2-year	55.6%	50.0%	0.795
Overall	57.1% (44)	83.3% (90)	<0.001
VAS Leg			
6-weeks	40.8%	61.2%	0.043
12-weeks	50.0%	63.9%	0.223
6-months	56.3%	56.3%	1.000
1-year	52.4%	66.7%	0.329
2-year	44.4%	77.8%	0.147
Overall	61.0% (36)	77.2% (44)	0.060
ODI			
6-weeks	16.0%	28.6%	0.133
12-weeks	34.2%	44.7%	0.335
6-months	50.0%	52.8%	0.819
1-year	33.3%	33.3%	1.000
2-year	55.6%	55.6%	1.000
Overall	46.7% (28)	60.0% (36)	0.143
SF-12 PCS			
6-weeks	34.1%	53.6%	0.102
12-weeks	58.3%	82.6%	0.052
6-months	71.4%	77.3%	0.640
1-year	73.9%	75.0%	0.935
2-year	75.0%	81.8%	0.675
Overall	72.0% (36)	83.3% (30)	0.220
PROMIS PF			
6-weeks	23.8%	41.7%	0.135
12-weeks	46.7%	64.0%	0.199
6-months	68.0%	66.7%	0.921
1-year	76.2%	70.0%	0.655
2-year	55.6%	50.0%	0.809
Overall	67.4% (29)	74.3% (26)	0.510

*p-value calculated with chi-squared analysis

group showed an ODI and SF-12 PCS improvement of 13.8 and 9.4 points and the severe back pain group showed an improvement of 19.4 and 7.8 points respectively. Furthermore, in 107 patients with degenerative scoliosis treated by LLIF, Philips et al (2013) reported statistically significant mean improvements at 2-year follow-up in ODI scores and VAS scores for back and leg pain of 21.5, 3.4, and 3.5, respectively. Similarly, Kotwal et al (2015) analyzed 118 patients undergoing LLIF and found ODI, VAS score, and SF-12 PCS improvements of 12.9, 4.6, and 11.1 at 2-year follow up, respectively. In our study, the moderate preoperative back pain cohort showed a 2-year improvement of 13.3 for ODI, 1.7 for VAS Back, 2.1 for VAS Leg, and 11.7

for SF-12. The severe back pain group demonstrated improvements of 10, 2.5, 2.0, and 14.6 for respective measures. Overall, this study's PROM percentage and score differences reflect comparable improvements in VAS back pain and leg pain, inferior outcomes with regard to disability, and superior outcomes in physical function relative to other studies.

Examining the present study's data further, though the moderate preoperative back pain group reported significantly lower absolute VAS back pain and ODI scores and higher absolute overall physical function scores postoperatively, it must be noted that their mean baseline scores were significantly better than those in the severe VAS back

pain cohort. Interestingly, when minimum clinically significant difference achievements were calculated, we found that patients in the VAS Back ≥ 7 group demonstrated an overall clinically significant improvement in their back pain (83.3% vs. 57.1%, $p < .001$) and near-significant overall improvement in their leg pain (77.2% vs. 61.0%, $p = .06$) compared to the moderate back pain cohort. Thus, taking both sets of findings into consideration, it would be reasonable to recommend LLIF more strongly in patients with degenerative lumbar spinal pathologies who present with a VAS back pain score ≥ 7 as it more likely can result in a clinically significant improvement in back pain. Conversely stated, surgical intervention in patients with a VAS back pain score < 7 may lead to improvements in patient-reported outcome measures as described above but is less likely to result in a clinically significant improvement compared to intervention in patients with more severe preoperative back pain.

LIMITATIONS

This study has several limitations. First, as with any retrospective analysis of prospectively collected databases, data entry and manipulation errors are possible. Second, it is important to note that these data represent procedures performed by one spine surgeon at one quaternary level medical center in the United States. As such, the findings previously discussed were limited to a patient population that consisted of mostly healthy [non-diabetic (81.6%), non-smoking (85.3%), ASA < 3 (70.1%)] Caucasians (80.8%) covered most often through private insurance (62.8%). Thus, the generalizability of this study's findings must be taken into consideration before being applied to a novel population. Third, LLIF specific complications - such as hip flexion dysesthesia/weakness, neurologic injury, vascular injury, visceral injury, and subsidence - that were examined in other comparable investigations (Marchi et al. 2013; Kim et al. 2013; Tormenti et al. 2010; Aichmair et al. 2015; Balsano et al. 2015; Tohmeh, Rodgers, and Peterson 2011; Lee et al. 2013) were not analyzed in this study.

FUTURE DIRECTIONS

Future studies can consider examining differences in pain, disability, and functional status beyond two years. Also, as mentioned previously, future studies can also consider examining the relationship between preoperative severity of pain measured through the VAS and the severity of spinal pathology as determined through radiographic measurement. Furthermore, other investigations might consider performing a similar analysis by initially stratifying patients by VAS Leg, ODI, SF-12 PCS, PROMIS PF, or another validated PROM assessment tool to understand if any of these PROMs provide greater predictive potential for postoperative outcomes than the VAS Back.

CONCLUSION

Patients in both preoperative back pain severity cohorts demonstrated significant long term clinical improvement from their respective preoperative baselines to 2-years postoperatively in back pain, leg pain, physical function, and general disability. Patients with severe preoperative back pain (VAS ≥ 7), however, demonstrated significantly inferior absolute short (6 weeks-6 months) and long-term (2-year) mean outcome scores for back pain and general disability when compared with their moderate preoperative back pain (VAS < 7) peers. However, patients with severe preoperative back pain achieved an overall MCID in VAS back pain in a significantly higher percentage of patients compared to their moderate preoperative back pain peers. Thus, taking both PROM and MCID findings into consideration, it would be reasonable to recommend LLIF more strongly in patients with degenerative lumbar spinal pathologies who present with a VAS back pain score ≥ 7 as it is more likely to result in a clinically significant

Submitted: June 16, 2022 EDT, Accepted: August 01, 2022 EDT



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-NC-ND-4.0). View this license's legal deed at <https://creativecommons.org/licenses/by-nc-nd/4.0> and legal code at <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> for more information.

REFERENCES

- Ahmadian, Amir, Sean Verma, Gregory M. Mundis, Rod J. Oskouian, Donald A. Smith, and Juan S. Uribe. 2013. "Minimally Invasive Lateral Retroperitoneal Transpoas Interbody Fusion for L4–5 Spondylolisthesis: Clinical Outcomes." *Journal of Neurosurgery: Spine* 19 (3): 314–20. <https://doi.org/10.3171/2013.6.spine1340>.
- Aichmair, Alexander, Gary A. Fantini, Sean Garvin, James Beckman, and Federico P. Girardi. 2015. "Aortic Perforation during Lateral Lumbar Interbody Fusion." *Journal of Spinal Disorders & Techniques* 28 (2): 71–75. <https://doi.org/10.1097/bsd.0000000000000067>.
- Arnold, Paul M., Karen K. Anderson, and Robert A. McGuire. 2012. "The Lateral Transpoas Approach to the Lumbar and Thoracic Spine: A Review." *Surgical Neurology International* 3 (4): 198. <https://doi.org/10.4103/2152-7806.98583>.
- Balsano, Massimo, Stefano Carlucci, Marija Ose, and Luca Boriani. 2015. "A Case Report of a Rare Complication of Bowel Perforation in Extreme Lateral Interbody Fusion." *European Spine Journal* 24 (S3): 405–8. <https://doi.org/10.1007/s00586-015-3881-6>.
- Bernstein, David N., Kathleen Fear, Addisu Mesfin, Warren C. Hammert, David J. Mitten, Paul T. Rubery, and Judith F. Baumhauer. 2019. "Patient-Reported Outcomes Use during Orthopaedic Surgery Clinic Visits Improves the Patient Experience." *Musculoskeletal Care* 17 (1): 120–25. <https://doi.org/10.1002/msc.1379>.
- Campbell, Peter G., Pierce D. Nunley, David Cavanaugh, Eubulus Kerr, Philip Andrew Utter, Kelly Frank, and Marcus Stone. 2018. "Short-Term Outcomes of Lateral Lumbar Interbody Fusion without Decompression for the Treatment of Symptomatic Degenerative Spondylolisthesis at L4–5." *Neurosurgical Focus* 44 (1): E6. <https://doi.org/10.3171/2017.10.focus17566>.
- Finkelstein, Joel A., and Carolyn E. Schwartz. 2019. "Patient-Reported Outcomes in Spine Surgery: Past, Current, and Future Directions: JNSPG 75th Anniversary Invited Review Article." *Journal of Neurosurgery: Spine* 31 (2): 155–64. <https://doi.org/10.3171/2019.1.spine18770>.
- Hoy, Damian, Lyn March, Peter Brooks, Fiona Blyth, Anthony Woolf, Christopher Bain, Gail Williams, et al. 2014. "The Global Burden of Low Back Pain: Estimates from the Global Burden of Disease 2010 Study." *Annals of the Rheumatic Diseases* 73 (6): 968–74. <https://doi.org/10.1136/annrheumdis-2013-204428>.
- Kim, Moon-Chan, Hung-Tae Chung, Jae-Lim Cho, Dong-Jun Kim, and Nam-Su Chung. 2013. "Subsidence of Polyetheretherketone Cage after Minimally Invasive Transforaminal Lumbar Interbody Fusion." *Journal of Spinal Disorders & Techniques* 26 (2): 87–92. <https://doi.org/10.1097/bsd.0b013e318237b9b1>.
- Kotwal, Suhel, Satoshi Kawaguchi, Darren Lebl, Alexander Hughes, Russel Huang, Andrew Sama, Frank Cammisa, and Federico Girardi. 2015. "Minimally Invasive Lateral Lumbar Interbody Fusion: Clinical and Radiographic Outcome at a Minimum 2-Year Follow-Up." *Journal of Spinal Disorders & Techniques* 28 (4): 119–25. <https://doi.org/10.1097/bsd.0b013e3182706ce7>.
- Lee, Yu-Po, Gilad J. Regev, Justin Chan, Bing Zhang, William Taylor, Choll W. Kim, and Steven R. Garfin. 2013. "Evaluation of Hip Flexion Strength Following Lateral Lumbar Interbody Fusion." *The Spine Journal* 13 (10): 1259–62. <https://doi.org/10.1016/j.spinee.2013.05.031>.
- Marchi, Luis, Nitamar Abdala, Leonardo Oliveira, Rodrigo Amaral, Etevaldo Coutinho, and Luiz Pimenta. 2013. "Radiographic and Clinical Evaluation of Cage Subsidence after Stand-Alone Lateral Interbody Fusion." *Journal of Neurosurgery: Spine* 19 (1): 110–18. <https://doi.org/10.3171/2013.4.spine12319>.
- McCormick, J. D., B. C. Werner, and A. L. Shimer. 2013. "Patient-Reported Outcome Measures in Spine Surgery." *Journal of the American Academy of Orthopaedic Surgeons* 21 (2): 99–107. <https://doi.org/10.5435/jaaos-21-02-99>.
- Menendez, Joshua York, Nidal Bassam Omar, Gustavo Chagoya, Borna Ethan Tabibian, Galal Ashraf Elsayed, Beverly Claire Walters, Barton Lucius Guthrie, and Mark Norman Hadley. 2019. "Patient Satisfaction in Spine Surgery: A Systematic Review of the Literature." *Asian Spine Journal* 13 (6): 1047–57. <https://doi.org/10.31616/asj.2019.0032>.
- Mobbs, R.J., K. Phan, G. Malham, K. Seex, and P.J. Rao. 2015. "Lumbar Interbody Fusion: Techniques, Indications and Comparison of Interbody Fusion Options Including PLIF, TLIF, MI-TLIF, OLIF/ATP, LLIF and ALIF." *J Spine Surg* 1 (1): 2–18.
- Ozgun, Burak M., Henry E. Aryan, Luiz Pimenta, and William R. Taylor. 2006. "Extreme Lateral Interbody Fusion (XLIF): A Novel Surgical Technique for Anterior Lumbar Interbody Fusion." *The Spine Journal* 6 (4): 435–43. <https://doi.org/10.1016/j.spinee.2005.08.012>.
- Patel, A.A., M. Zfass-Mendez, N.H. Lebowitz, et al. 2015. "Minimally Invasive Versus Open Lumbar Fusion: A Comparison of Blood Loss, Surgical Complications, and Hospital Course." *Iowa Orthop J* 35: 130–34.
- Phillips, Frank M., Robert E. Isaacs, William Blake Rodgers, Kaveh Khajavi, Antoine G. Tohmeh, Vedat Deviren, Mark D. Peterson, Jonathan Hyde, and Mark Kurd. 2013. "Adult Degenerative Scoliosis Treated with XLIF: Clinical and Radiographical Results of a Prospective Multicenter Study with 24-Month Follow-Up." *Spine* 38 (21): 1853–61. <https://doi.org/10.1097/brs.0b013e3182a43f0b>.

- Rodgers, W. Blake, Edward J. Gerber, and Jamie Patterson. 2011. "Intraoperative and Early Postoperative Complications in Extreme Lateral Interbody Fusion: An Analysis of 600 Cases." *Spine* 36 (1): 26–32. <https://doi.org/10.1097/brs.0b013e3181e1040a>.
- Salzmann, Stephan N., Jennifer Shue, and Alexander P. Hughes. 2017. "Lateral Lumbar Interbody Fusion—Outcomes and Complications." *Current Reviews in Musculoskeletal Medicine* 10 (4): 539–46. <https://doi.org/10.1007/s12178-017-9444-1>.
- Tohmeh, Antoine G., William Blake Rodgers, and Mark D. Peterson. 2011. "Dynamically Evoked, Discrete-Threshold Electromyography in the Extreme Lateral Interbody Fusion Approach." *Journal of Neurosurgery: Spine* 14 (1): 31–37. <https://doi.org/10.3171/2010.9.spine09871>.
- Tormenti, Matthew J., Matthew B. Maserati, Christopher M. Bonfield, David O. Okonkwo, and Adam S. Kanter. 2010. "Complications and Radiographic Correction in Adult Scoliosis Following Combined Transpoas Extreme Lateral Interbody Fusion and Posterior Pedicle Screw Instrumentation." *Neurosurgical Focus* 28 (3): E7. <https://doi.org/10.3171/2010.1.focus09263>.
- Wong, Arnold YL, Jaro Karppinen, and Dino Samartzis. 2017. "Low Back Pain in Older Adults: Risk Factors, Management Options and Future Directions." *Scoliosis and Spinal Disorders* 12 (1). <https://doi.org/10.1186/s13013-017-0121-3>.
- Youssef, Jim A., Paul C. McAfee, Catherine A. Patty, Erin Raley, Spencer DeBauche, Erin Shucosky, and Liana Chotikul. 2010. "Minimally Invasive Surgery: Lateral Approach Interbody Fusion." *Spine* 35 (Supplement): S302–11. <https://doi.org/10.1097/brs.0b013e3182023438>.